AnGes, Inc. (AMGXF)
- Previous Close
0.0000 - Open
0.5160 - Bid 0.4143 x --
- Ask 0.4943 x --
- Day's Range
0.5160 - 0.5419 - 52 Week Range
0.3353 - 0.5419 - Volume
4,000 - Avg. Volume
0 - Market Cap (intraday)
117.809M - Beta (5Y Monthly) 1.50
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7900 - Earnings Date May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AnGes, Inc. engages in the research and development of gene-based medical products. It develops HGF gene therapy product for the treatment of ischemic diseases; NF-?B Decoy Oligo DNA for chronic discogenic lumber back pain; and DNA vaccines for the treatment of hypertension and cervical intraepithelial neoplasia, as well as intranasal formulation of the COVID-19 vaccine. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.
www.anges.co.jpRecent News: AMGXF
View MorePerformance Overview: AMGXF
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMGXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMGXF
View MoreValuation Measures
Market Cap
159.82M
Enterprise Value
149.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
19.86
Price/Book (mrq)
6.05
Enterprise Value/Revenue
22.79
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.93%
Return on Equity (ttm)
-199.09%
Revenue (ttm)
643M
Net Income Avi to Common (ttm)
-28.13B
Diluted EPS (ttm)
-0.7900
Balance Sheet and Cash Flow
Total Cash (mrq)
1.71B
Total Debt/Equity (mrq)
12.57%
Levered Free Cash Flow (ttm)
-2.67B